Cyclosporine in the treatment of chronic urticaria: a real-world study on efficacy and safety

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068607

Enrollment

Unknown

Registered

2023-02-24

Start date

2023-02-28

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urticaria

Interventions

Cyclosporine treatment group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Patients with chronic spontaneous urticaria and / or artificial urticaria who meet the relevant diagnostic criteria 2 Patients with chronic urticaria who still have the following conditions after standard treatment according to CU guidelines: patients with UAS 7 >= 7 or DLQI >= 6 points 3 Who have been treated with cyclosporine soft capsules for more than 6 months and have more than 3 follow-up records (allowed to be treated with other drugs at the same time)

Exclusion criteria

Exclusion criteria: 1 Patients with hypertension or severe systemic diseases 2 Patients with severe impairment of liver and kidney 3 Patients with contraindications to glucocorticoid / cyclosporine use 4 Patients in pregnancy / lactation

Design outcomes

Primary

Measure	Time frame
urticaria activity score;	—

Secondary

Measure	Time frame
chronic urticaria quality of life question-naire;Dermatology Life Quality Index;urticaria control test;	—

Countries

China

Contacts

Public ContactLin Youkun

The First Affiliated Hospital of Guangxi Medical University

linyoukun7@aliyun.com13507883737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026